

**Germline sequencing of DNA-damage-repair genes in two hereditary prostate cancer cohorts reveals new disease risk-associated gene variants.**

Georgea R. Foley <sup>1</sup>, James R. Marthick <sup>1</sup>, Sionne E. Lucas <sup>1</sup>, Kelsie Raspin <sup>1</sup>, Annette Banks <sup>1</sup>, Janet L. Stanford <sup>2</sup>, Elaine A. Ostrander <sup>3</sup>, Liesel M. FitzGerald <sup>1\*</sup>, and Joanne L. Dickinson <sup>\*\*^</sup>

<sup>1</sup>Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia. Tel +3 61 3 62267700

<sup>2</sup>Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., M4-B874, Seattle, WA 98109-1024, USA. Tel. (206) 667-500

<sup>3</sup>Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA. Tel. (301) 594-5284

\* These authors are joint senior authors

^ Corresponding Author: Tel: +61 3 6226 7622; Email: [jo.dickinson@utas.edu.au](mailto:jo.dickinson@utas.edu.au); ORCID ID: 0000-0003-4621-1703

**Conflicts of Interest:** The authors declare no potential conflicts of interest.

**Running Title:** Novel DNA-damage repair genes in prostate cancer.

**Key Words:** rare high-risk genes; prostate cancer, DNA repair, genetic susceptibility; germline variants.

**Abstract:** 194 words

## ABSTRACT

**Background:** Knowledge of rare, inherited variants in DNA damage repair (DDR) genes is informing clinical management in common cancers. However, defining the rare disease-associated variants in prostate cancer (PrCa) is challenging due to their low frequency.

**Methods:** Here, whole-genome and -exome sequencing data from two independent, high-risk Australian and North American familial PrCa datasets were interrogated for novel, rare DDR variants. Segregating, high-risk, likely pathogenic DDR gene variants were identified and subsequently genotyped in 1,963 individuals (700 familial and 459 sporadic PrCa cases, 482 unaffected relatives, and 322 screened controls) and association analyses performed accounting for relatedness ( $M_{QLS}$ ). **Results:** Rare variants significantly associated with PrCa risk were identified in *ERCC3* (rs145201970,  $p=2.57 \times 10^{-4}$ ) and *BRIP1* (rs4988345,  $p=0.025$ ) in the combined datasets. A *PARP2* (rs200603922,  $p=0.028$ ) variant in the Australian dataset and a *MUTYH* (rs36053993,  $p=0.031$ ) variant in the North American dataset were also associated with PrCa risk. No evidence for a younger age or higher-grade disease at diagnosis was evident in variant carriers. **Conclusions:** Here, we provide new evidence for four novel germline DDR PrCa risk variants. Defining the full spectrum of PrCa associated DDR genes is important for effective clinical screening and disease management.

## Abbreviations

BER – base excision repair

CADD – Combined Annotation-Dependent Depletion

DDR – DNA damage repair

FHCC – Fred Hutchinson Cancer Centre

GS – Gleason Score

MAF – minor allele frequency

M<sub>QLS</sub> – modified quasi-likelihood score

NFE – non-Finnish Europeans

PARPi – poly (ADP-ribose) polymerase inhibitors

PCOR-TAS – Prostate Cancer Outcomes Registry – Tasmania

PrCa – prostate cancer

PSA – prostate specific antigen

TCR – Tasmanian Cancer Registry

WES – whole-exome sequencing

WGS – whole-genome sequencing

## BACKGROUND

Prostate cancer (PrCa) is responsible for a significant proportion of cancer-related deaths in men worldwide and presents a substantial health burden in terms of morbidity, mental health, and economic costs associated with treatment. A considerable percentage of men with advanced disease harbour clinically actionable variants, many of which are aberrations in DNA damage repair (DDR) genes (1, 2, 3, 4, 5, 6). Notably, germline variants in these genes have been observed in 8-16% of metastatic PrCa patients (1, 4, 7).

Despite recognition of their potential, there remains a significant gap in our understanding of the spectrum of DDR gene variants contributing to PrCa risk (7, 8, 9, 10, 11). Variants in several of these genes, particularly *ATM* and *BRCA1/2*, have been associated with a poorer prognosis, differing responses to treatment, and more aggressive disease (12, 13, 14, 15, 16). Importantly, tumours harbouring loss-of-function mutations in DDR genes exhibit a therapeutic response to poly (ADP-ribose) polymerase inhibitors (PARPi)(17) and platinum-based chemotherapy (18). Thus, screening for clinically actionable germline variants in PrCa patients, particularly those with a significant family history together with advanced disease, represents an important strategy to improve PrCa outcomes. The rarity of these variants in population-based PrCa datasets, which represent the majority of PrCa DDR gene discovery studies to date, has hampered research efforts. In addition, many of these studies have not differentiated between germline and acquired mutations, and those variants that have been identified remain largely of unknown clinical significance.

Curation of the full spectrum of DDR genetic variants contributing to PrCa risk has significant potential in the healthcare setting, where precision medicine can be implemented for both diagnosis and treatment. Moreover, the observation that germline and acquired mutations are frequently identified in the same DDR genes underscores the importance of these pathways in tumour development. Here, we interrogated whole-genome and -exome germline data from two high-risk familial PrCa datasets with the aim of identifying novel, rare DDR gene variants contributing to PrCa risk.

## **METHODS**

The aim of this study was to identify novel rare putative pathogenic variants in DDR genes using two large familial prostate cancer genetic cohorts from Australia and North America.

### **Study Resources**

This study utilises clinicopathological and genetic data available from two independent PrCa resources: the Australian resource, consisting of the Tasmanian Familial Prostate Cancer Study and the population-based Tasmanian Prostate Cancer Case-Control Study, and the North American resource, consisting of the Prostate Cancer Genetic Research Study (*PROGRESS*) from the Fred Hutchinson Cancer Center (FHCC).

The Tasmanian Familial Prostate Cancer Study included 73 PrCa families comprising DNA from 379 affected men and 471 unaffected male and female relatives of Northern European heritage (19, 20, 21). The study was initiated in Tasmania in the late 1990s, prior to the implementation of wide-spread prostate-specific antigen (PSA) testing as a PrCa screening tool. Families with more than two affected first-degree relatives spanning two or more generations are included and were identified through interrogation of the Menzies Genealogical database and the Tasmanian Cancer Registry (TCR), in addition to collaboration with local clinicians.

The second, population-based Tasmanian Prostate Cancer Case-Control Study comprises 459 cases and 322 male controls of Northern European ancestry (19, 20, 21). Cases were identified from the TCR. Controls were selected at random from the Tasmanian electoral roll, frequency matched by five-year age groups to the cases, and checked bi-annually against the TCR for PrCa diagnosis.

The FHCC resource comprises *PROGRESS*, which includes >300 PrCa families from across North America (22). Whole exome sequencing (WES) data were available for 130 families, which included 11 older unaffected men and 321 affected men. Men prioritised for WES were those diagnosed with an early-onset/aggressive disease phenotype, uncle-nephew and/or cousin pairs from families with densely aggregated affected men.

Details of the clinical data available for these resources are presented in Table 1.

Additionally, age-at-diagnosis and Gleason score (GS) data from 2,126 participants enrolled in the population-based Prostate Cancer Outcomes Registry - Tasmania (PCOR-TAS) were available for clinicopathological analyses. PCOR-TAS was established in 2015, with an aim to improve all aspects of the quality of care for men diagnosed with PrCa. The opt-out registry is an ongoing initiative that records data on the diagnosis, treatment, outcomes, and quality of life for all Tasmanians diagnosed with PrCa. Details of the registry, including data collection methods, have been described previously (23). As of the 15<sup>th</sup> of July 2021, 2,126 men had been recruited into PCOR-TAS, with ~3% having opted out of the registry.

### **Whole-Genome Sequencing and Bioinformatic Sequence Analysis**

Whole-genome sequencing (WGS) data were generated from germline DNA (additional details: Supplementary Method 1) for 54 individuals from eight Australian families (Supplementary Table S1) and seven unaffected men from the Australian Case-Control Study.

Of the familial individuals, 43 had been diagnosed with PrCa, with the remaining individuals comprising a female relative with a self-reported breast cancer diagnosis (n=1) and unaffected male relatives (n=10). WGS (mean coverage = 38.7x; range = 29.2x-49.8x) was completed in five instalments at the Australian Genome Research Facility (Melbourne, Australia), the Ramaciotti Centre for Genomics (Sydney, Australia), and the Texas Biomedical Research Institute (San Antonio, Texas). Sequence data were aligned to the hg19 reference genome with BWA-MEM (24) and variants were called with GATK (25), using bcbio (26).

### **Variant Filtering, Prioritisation, and Validation**

A panel of 35 genes involved in DDR pathways was compiled (Table 2), in addition to the established PrCa risk gene, *HOXB13* (27). Variants located in a genomic window 1000bp up and downstream of the nominated candidate genes were extracted from WGS data using bcftools (28) and annotated using ANNOVAR (29). Included genes and genomic positions can be found in Supplementary Table S2.

Variant filtering and prioritisation occurred according to a range of criteria (Figure 1). Variants were filtered to include those with a minor allele frequency (MAF) <1% in gnomAD non-Finnish Europeans (NFE) and Combined Annotation-Dependent Depletion (CADD) score >15, with further prioritisation informed by predicted mutation function (e.g., nonsense > missense > splicing > synonymous). Variants were excluded if present in >1 of the seven screened unaffected male control genomes, or if present only in PrCa unaffected familial individuals.

Short-listed variants (MAF <1%, CADD >15, nonsynonymous, and carried by >1 PrCa case; (Figure 1), which had been validated by Sanger sequencing on the ABI 3500 Genetic Analyser (Applied Biosystems), were genotyped in additional non-WGS relatives to determine segregation in the relevant discovery family. Primers were designed to amplify fragments approximately 300bp in length for each of the selected variants. Primer sequences are presented in Supplementary Table S3, and PCR conditions are available upon request.

### **Additional Genotyping in Expanded Australian Resources and Statistical Analysis**

Six prioritised variants (Figure 1) were genotyped in the full Australian familial and case-control resources, using TaqMan™ genotyping assays (ThermoFisher Scientific; Supplementary Table S4) on the LightCycler® 480 system (Roche). Existing whole exome data were interrogated for prioritised gene variants in the *PROGRESS* study individuals. Association between genotyped variants and PrCa risk was tested for using Modified Quasi-Likelihood Score ( $M_{QLS}$ ) analysis (30) (additional details: Supplementary Method 2). Population prevalence of PrCa was set at one in seven, and the analyses were conducted in the Australian familial and case-control datasets alone, the FHCC *PROGRESS* cohort alone, and all datasets combined. For DDR variants significantly associated with PrCa risk, diagnosis age of variant carriers was compared with population-based PCOR-TAS cases (TAS) or the full *PROGRESS* cohort (FHCC) and the proportion of variant carriers across several age-at-diagnosis categories (<50, <55, <60, <65, <70) was examined. GS at diagnosis of variant carriers was also recorded where available.

## RESULTS

### Clinical Characteristics of Australian and North American PrCa Resources

Clinical characteristics of the study resources are presented in Table 1. Age-at-diagnosis, time interval between diagnosis and death, and proportion of PrCa-specific deaths were similar across the datasets.

### Identification of Candidate Rare DDR PrCa Risk Variants

WGS data were interrogated for rare, potentially pathogenic variants in 35 DDR genes (Table 2). Initial filtering identified 30 variants in 20 genes, of which two in *HOXB13* and *RAD51C* have previously been shown to be significantly associated with PrCa risk in our Australian cohort (19, 20), providing proof-of-principle for our approach. Of the 28 remaining variants, four failed to validate via Sanger sequencing and were excluded from further investigation.

Additional non-WGS affected and unaffected relatives with DNA from each of the Australian discovery families underwent Sanger sequencing to determine segregation with disease of the remaining 24 variants (Table 3). Five variants were subsequently excluded: three variants that were each only present in a single affected man and two variants that were only present in a single affected man and one unaffected relative. The remaining 19 variants, *ATM* rs56128736, *BARD1* rs3738888, *BRCA1* rs28897673, *BRCA2* rs28897727, *BRCA2* rs55639415, *BRCA2* rs786202915, *BRIP1* rs4988345, *ERCC2* rs142568756, *ERCC3* rs145201970, *MRE11* rs777373591, *MSH6* rs142254875, *MUTYH* rs36053993, *PARP2* rs200603922, *PMS2* rs1554304601, *POLE* chr12: 133219216, *POLE* rs41561818, *PTEN* rs587779989, *PTEN* rs773513402, and *RECQL4* rs780723602, were present in at least two affected relatives from the Australian discovery cohort.

For further prioritisation, we then sought to determine whether any of the 19 variants were present in the North American *PROGRESS* families. Examination of exome data from 332 individuals revealed seven variants in 34 cases from 22 kindreds. Four variants, *ATM* rs56128736, *BRCA2* rs28897727, *ERCC3* rs145201970, and *MUTYH* rs36053993, were present in two or more PrCa cases in a single family (Table 3).



Six DDR variants, *BARD1* rs3738888, *BRCA2* rs28897727, *BRIP1* rs4988345, *ERCC3* rs145201970, *MUTYH* rs36053993, and *PARP2* rs200603922, that segregated with disease in an Australian PrCa family and were present in two or more *PROGRESS* families, were selected for additional investigation (Table 3). These variants were genotyped in the extended Australian familial and case-control resources via TaqMan genotyping. All six variants were identified in additional individuals ( $n_{\text{range}}=9$  to 33; Supplementary Table S5) within the Australian datasets, and all except *MUTYH* rs36053993 were observed in additional familial PrCa cases. With the inclusion of the *PROGRESS* dataset, the *BARD1* rs3738888 and *BRIP1* rs4988345 variants were each observed in the most PrCa cases ( $n=22$ ), which included ten and nine sporadic cases, respectively. The predicted pathogenicity of these variants was determined using multiple bioinformatic tools (additional details: Supplementary Method 3) and outputs are shown in Table 4.

### Statistical Analysis

Genotypes were available for six variants in 1,963 individuals, including 700 familial and 459 sporadic PrCa cases overall.  $M_{\text{QLS}}$  association analysis permitted the inclusion of related and unrelated individuals while also appropriately controlling for Type 1 error (30). In the Australian dataset, a significant association was observed between *PARP2* rs200603922 and PrCa risk ( $p=0.028$ ), whilst in the *PROGRESS* dataset, a significant association was observed between *BRIP1* rs4988345 ( $p=0.034$ ), *ERCC3* rs145201970 ( $p=0.010$ ), and *MUTYH* rs36053993 ( $p=0.031$ ) and PrCa risk (Table 5). In the combined Australian and *PROGRESS* datasets, a significant association with PrCa risk was observed between *BRIP1* rs4988345 ( $p=0.025$ ) and *ERCC3* rs145201970 ( $p=2.57 \times 10^{-4}$ ). The *ERCC3* variant remains significant following Bonferroni correction for multiple testing. PrCa status of variant carriers is provided in Supplementary Table S5 and clinical characteristics of affected familial carriers are available upon request.

Age-at-diagnosis amongst variant carriers was compared to relevant population datasets (Figure 2) with a shift towards younger age-at-diagnosis observed, most evident in Australian sporadic carriers compared with the population-based PCOR-TAS cohort. While a slightly higher proportion of DDR variant carriers was observed in cases diagnosed before 55 years of age (9.4%; Table 6), variant carriers were relatively consistent at ~6% across the

remaining age at diagnosis categories (Table 6). Population data from PCOR-TAS reveals that ~20% of Tasmanian men are diagnosed with a  $GS \geq 8$ . Of men carrying a risk DDR variant, 23% (15/66) were diagnosed with  $GS \geq 8$ , while 58% (38/66) of rare variant carriers were diagnosed with a  $GS \leq 6$ .

## DISCUSSION

The discovery of rare, high-risk germline variants has long proven challenging due to their very low frequency, which substantially impacts power to detect significant statistical associations. However, there remains considerable impetus to characterise rare risk variants in DDR genes, especially considering the increasing availability of therapies targeting this pathway. In a candidate gene approach designed to take advantage of large familial PrCa resources, where rare risk variants are expected to be enriched, we examined massively parallel sequencing data from two independent datasets to identify rare, likely deleterious DDR variants. Subsequent analysis of 1,963 individuals from the Australian and *PROGRESS* datasets revealed statistically significant associations between rare variants in *ERCC3* and *BRIP1* and PrCa risk, with *ERCC3* surviving correction for multiple testing. In addition, a variant in *PARP2* was significantly associated with PrCa risk in the Australian dataset alone, while a variant in *MUTYH* was significantly associated with PrCa risk only in the *PROGRESS* dataset.

*ERCC3* encodes one of two ATP-dependent DNA helicases, which are core members of the nucleotide excision repair pathway. The *ERCC3* rs145201970 variant (MAF 0.17%), located in exon 7, causes an amino acid change at position 283 (p.R283C), which is predicted to disrupt the arginine-aspartic acid salt bridge via the inclusion of a more hydrophobic residue. The variant is located within two domains listed by Interpro as likely required for *ERCC3* protein function (31). Topka *et al.* comprehensively examined germline mutations in the *ERCC2*, 3, 4, and 5 genes in 16,712 patients affected by multiple different cancers (32). Numerous likely pathogenic/likely pathogenic loss of function (LoF) germline variants were observed in *ERCC3*, with rs145201970 (n=42) representing the second most observed LoF variant in this gene in cancer patients after rs34295337 (n=70)(32). While there are no previous reports describing rs145201970 as a PrCa risk variant, other germline pathogenic/likely pathogenic *ERCC3* variants in PrCa patients were recently reported by Kohaar *et al.* (33). Additionally, an intronic *ERCC3* variant has been previously associated with increased risk of biochemical recurrence after low-dose-rate prostate brachytherapy, potentially due to reduced mRNA expression in variant carriers (34). In breast cancer, a recurrent truncating mutation has been associated with familial disease (35, 36). *In vitro* studies have demonstrated mutations

in *ERCC3* impair DNA repair capability and confer a selective sensitivity to Irofulven, a sesquiterpene that has demonstrated some efficacy in clinical trials for metastatic PrCa (32).

*BRIP1* is a member of the Fanconi Anaemia gene family and functions in the double-strand break repair pathway, interacting closely with *BRCA1*. The rare rs4988345 variant (MAF 0.43%) is in exon 5. As a result of the p.R173C amino acid change, there is a loss of positive charge and a more hydrophobic residue introduced within a helicase ATP-binding domain and a region annotated as a nuclear localization signal. *BRIP1* rs4988345 has been previously identified in a study enriched for familial PrCa but was only observed in a single PrCa case (0.52%)(37). Other rare *BRIP1* variants were detected in five hereditary PrCa cases (MAF <1%)(38), however, no statistical analyses were performed due to their low frequency. A study in breast cancer has linked the rs4988345 variant to disease susceptibility through impairing protein translocation to the nucleus (39). *BRIP1* has been included on screening panels for several clinical trials investigating the response of metastatic PrCa patients with DDR defects to Olaparib, a PARPi (ClinicalTrials.gov Identifier: NCT02987543)(40). A cohort of that study comprised men harbouring mutations in 12 DDR genes, including *BRIP1*, however, only four individuals were identified as carriers of a variant in this gene, below the pre-set threshold for statistical analysis. Evaluation of *BRIP1* has also been included in the Phase 2 TRITON2 trial (ClinicalTrials.gov Identifier: NCT02952534) where one patient with a *BRIP1* variant responded to the PARPi, Rucaparib (41).

*PARP2* is a poly (ADP-ribose) polymerase involved in the base excision repair pathway (BER), and rs200603922 is located in the first exon (p.R15G). This variant (MAF 0.12%) has previously been observed to partially segregate with PrCa in familial cases who tested negative for *BRCA1* and *BRCA2* mutations (42). Although several bioinformatic tools predict the variant allele to be benign (Table 4), the R15G amino acid change introduces a more hydrophobic residue, which may impact protein interactions and the phosphorylation of distal residues. There is one other report of a *PARP2* variant, rs3093926 (MAF 4.2%), segregating in a PrCa pedigree, but the contribution of this variant to PrCa risk remains undetermined (43) and though common, it was not observed in our Australian discovery families. *PARP2* mutations have been associated with breast cancer risk (44), but similar to PrCa, their functional impact remains unclear. However, *PARP2* remains of interest given the

ongoing development of PARPi. Though most primarily target *PARP1*, some, such as Niraparib (45), also affect *PARP2*, which may be relevant when assessing therapeutic PARPi in men with *PARP2* mutations.

*MUTYH* encodes a DNA glycosylase involved in oxidative DDR and the BER pathway. The rs36053993 variant (MAF 0.47%) results in an amino acid change from a neutral residue to a negatively charged, less hydrophobic residue (p.G368D), with this change located in the highly conserved nudix hydrolase domain. The NCBI human variant database, ClinVar, lists this variant as pathogenic/likely pathogenic arising from its association with *MUTYH*-associated polyposis, an autosomal recessive hereditary condition typified by the development of colorectal carcinomas. Kohaar *et al.* (2022) previously reported the rs36053993 SNP in germline samples from PrCa patients (33). Others have also reported several pathogenic/likely pathogenic variants in *MUTYH*, including a study reporting 1.8% of 1,351 PrCa cases (46), while another reported 2.4% of 3,607 PrCa cases as carrying pathogenic variants in this gene (47). Furthermore, reduced gene and protein expression of *MUTYH* in prostate tumours has been associated with an increase in total somatic mutations, which may result from impaired DDR capacity (48).

In this study, the strategy for filtering and prioritisation of variants was developed to detect highly penetrant, rare DDR gene variants that may contribute to familial PrCa risk. It is notable that rare germline variants predicted to be deleterious have been previously observed in *BRIP1* (n=7), *ERCC3* (n=8), *MUTYH* (n=10), and *PARP2* (n=5) in a cohort of 5,545 non-aggressive and aggressive sporadic PrCa cases (11). While no statistically significant association with aggressive disease risk was observed, due to the very low frequency of these variants, their association with PrCa risk in general was not explored in this case-only cohort (see Supplementary Tables, Darst *et al.* (11)). Notably, this study examined 5,545 cases and statistically significant associations with aggressive disease were only demonstrated for previously known PrCa risk genes, *BRCA2* and *PALB2*, with a nominal association seen for *ATM*. This highlights the fact that the innate rarity of DDR gene variants presents a significant challenge for rare variant evaluation, even in larger sporadic case datasets. Our approach was designed to maximise power by seeking to identify rare variants enriched in two large familial PrCa cohorts. However, it is possible that additional rare,

disease-associated variants were not detected due to not being present in the Australian WGS discovery cases. It was also necessary to restrict follow-up to only those candidate variants observed in more than one North American family, as the rareness of these variants impacts statistical power to detect associations. However, this may have resulted in risk variants associated with disease in the Australian cohort being missed, e.g., *ATM* rs56128736. Furthermore, instances where prioritised variants were subsequently not found to be associated with PrCa could be attributed to their rarity and, thus, lack of statistical power. Further examination of additional familial and population-based datasets is therefore required to establish the necessary evidence-base to inform clinical decision making. Concurrently, it is worth considering the expansion of candidate gene screening strategies in current clinical trials of PARPi and in current germline testing guidelines for men with a family history of PrCa.

Examining rare variant association with clinicopathological variables presented significant challenges, again due to their rarity, but also due to biases introduced by recruitment strategies. For example, while the aim was to collect all known relatives with PrCa in the Australian and *PROGRESS* familial cohorts, population-based cases with an early age-at-diagnosis were targeted for recruitment to the Australian case-control study.

Carriers of putative pathogenic DDR variants were slightly more frequently observed in the earlier age-at-diagnosis group, and mildly increased in the  $GS \geq 8$ -at-diagnosis group when compared with the population-based PCOR-TAS cohort. However, it is notable that the majority of variant carriers were diagnosed with a  $GS \leq 6$  (58%) and/or at age  $\geq 65$  years (53%), consistent with the findings of Darst *et al.* (11), where carriers of DNA repair mutations were, on average, diagnosed only  $\sim 1$  year younger than non-carriers. Taken together, these findings raise the question as to whether limiting screening for putative genetic DDR variants to very early-onset ( $< 50$  years) or only high-grade disease patients is likely to result in a substantial proportion of DDR variant carriers being excluded from testing, and subsequently denied access to effective treatment modalities.

**Conclusions:** This study implicates several additional DDR genes as contributors to inherited genetic risk of PrCa. The existing evidence that rare DDR gene variants are associated with aggressive disease and the growing use of cancer therapies targeting this pathway highlights

the potential significance of these findings. However, this study raises the concern that confining genetic screening to only those patients with early onset and/or high-grade PrCa may result in a missed opportunity for some men to receive effective, targeted gene-based therapies.

## **ADDITIONAL INFORMATION**

### **Acknowledgements**

We are greatly indebted to the participants of our prostate cancer studies, the Tasmanian Cancer Registry staff, Tasmanian urologists, pathologists, and the wider Tasmanian clinical and research community for their ongoing support. We also thank the individuals participating in the FHCRC *PROGRESS* study.

### **Authors' Contributions**

Conceptualization – LMF, JLD; Data curation – GRF, JRM, SEL, KR; Formal Analysis – GRF; Funding acquisition – LMF, JLD; Investigation – GRF, JRM, SEL, LMF, JLD; Methodology – GRF, JRM, SEL, KR, LMF, JLD; Project administration – JLS, LMF, JLD; Resources – JRM, AB, JLS, EAO, LMF, JLD; Supervision – LMF, JLD; Validation – GRF, JRM, JLS, EAO; Writing – original draft – GRF, JRM, LMF, JLD; Writing – review & editing - all authors.

### **Ethics Approval and Consent to Participate.**

Ethics approval for this study was obtained from the Human Research Ethics Committee Tasmania, Australia (H0017040). Written informed consent was gained for all participants. PCOR-TAS participants consented to their data being used for ethically approved research and ethics approval to use these data was obtained from the Tasmanian Health and Medical Human Research Ethics Committee, Australia (H0017095). The *PROGRESS* study was approved by the FHCRC's Institutional Review Board and informed consent was obtained from all study participants. All participants provided consent for inclusion of their data in publications.

### **Data Availability**

The data that supports the findings of this study are available in the article and its online supplementary material, or from the corresponding author upon reasonable request. The genome and exome sequencing data are not publicly available due to privacy or ethical restrictions.



## **Competing Interests**

The authors report no competing interests.

## **Funding Information**

This work was supported by grants from the Cancer Council Tasmania and IMPACT Perpetual Trustees (Betty Lowe Memorial Trust, grant number IPAP20210253), as well as the Royal Hobart Hospital Research Foundation (RHHRF); Cancer Australia; The Mazda Foundation; Max Bruce Trust; The Estate of Dr RA Parker; the Tasmanian Community Fund; the Robert Malcom Familial Prostate Cancer Bequest; the Fred Hutchinson Cancer Center (grant number P30 CA015704); and the Institute for Prostate Cancer Research of the University of Washington Medicine and Fred Hutchinson Cancer Center.

Individual support includes a Cancer Council Tasmania/College of Health and Medicine Scholarship to GRF; the National Cancer Institute of the National Institutes of Health (grant numbers R01 CA080122, U01 CA089600, K05 CA17514) to JLS; the National Human Genome Research Institute of the National Institutes of Health to EAO; a previous Cancer Council Tasmania/College of Health and Medicine Senior Research Fellowship and a current Williams Oncology RHHRF grant and Gerald Harvey University of Tasmania Senior Research Fellowship to LMF; and a previous Australian Research Council Future Fellowship and current Select Foundation Cancer Research Fellowship to JLD.

## REFERENCES

1. Castro E, Romero-Laorden N, del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. *Journal of Clinical Oncology*. 2019;37(6):490-503.
2. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. *JCO Precis Oncol*. 2017;2017.
3. Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 2019;116(23):11428-36.
4. Robinson D, Van Allen Eliezer M, Wu Y-M, Schultz N, Lonigro Robert J, Mosquera J-M, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. *Cell*. 2015;161(5):1215-28.
5. Holt C. Comprehensive Genetic Profiling Unravels Molecular Targets in Prostate Cancer. *Oncology Times*. 2019;41(14):9.
6. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. *Eur Urol*. 2013;63(5):920-6.
7. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *The New England journal of medicine*. 2016;375(5):443-53.
8. Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. *British Journal of Cancer*. 2021;124(3):552-63.
9. Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, et al. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. *PLOS Genetics*. 2018;14(4):e1007355.
10. Leongamornlert DA, Saunders EJ, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. *Eur Urol*. 2019;76(3):329-37.
11. Darst BF, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, et al. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. *JNCI: Journal of the National Cancer Institute*. 2021;113(5):616-25.
12. Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and Other DDR Genes in Prostate Cancer. *Cancers*. 2019;11(3).
13. Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *European Urology*. 2015;68(2):186-93.
14. Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. *European Urology*. 2017;71(5):740-7.
15. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. *British Journal of Cancer*. 2008;98(2):502-7.
16. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(14):1748-57.

17. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *New England Journal of Medicine*. 2015;373(18):1697-708.
18. Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, et al. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. *JCO Precis Oncol*. 2020;4:355-66.
19. FitzGerald LM, Raspin K, Marthick JR, Field MA, Malley RC, Thomson RJ, et al. Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. *Scientific Reports*. 2017;7.
20. Marthick JR, Raspin K, Foley GR, Blackburn NB, Banks A, Donovan S, et al. Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C. *European Journal of Cancer*. 2021;159:52-5.
21. Raspin K, FitzGerald LM, Marthick JR, Field MA, Malley RC, Banks A, et al. A rare variant in EZH2 is associated with prostate cancer risk. *Int J Cancer*. 2021;149(5):1089-99.
22. Stanford JL, FitzGerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. *Human Molecular Genetics*. 2009;18(10):1839-48.
23. Foley GR, Blizzard CL, Stokes B, Skala M, Redwig F, Dickinson JL, et al. Urban-rural prostate cancer disparities in a regional state of Australia. *Scientific Reports*. 2022;12(1):3022-.
24. Li HW. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv: Genomics*. 2013.
25. Van der Auwera G, O'Connor B. *Genomics in the Cloud: Using Docker, GATK, and WDL in Terra* (1st Edition); O'Reilly Media; 2020.
26. Brad Chapman RK, Lorena Pantano, Sergey Naumenko, Matthias De Smet, Luca Beltrame, Tetiana Khotiainsteva, Ilya Sytchev, Roman Valls Guimera, John Kern, Christian Brueffer, Vlad Savelyev, Guillermo Carrasco, Mario Giovacchini, Miiika Ahdesmaki, Paul Tang, Sehrish Kanwal, James J Porter, Steffen Möller, Vang Le, Alexandru Coman, bogdang989, Valentine Svensson, Brent Pedersen, Jeff Hammerbacher, Matt Edwards, Meeta Mistry, apastore, Peter Cock, Stephen Turner. *bcbio/bcbio-nextgen*. v.1.1.2.8 ed: Zenodo; 2021. p. Brad Chapman; Rory Kirchner; Lorena Pantano; Sergey Naumenko; Matthias De Smet; Luca Beltrame; Tetiana Khotiainsteva; Ilya Sytchev; Roman Valls Guimera; John Kern; Christian Brueffer; Vlad Savelyev; Guillermo Carrasco; Mario Giovacchini; Miiika Ahdesmaki; Paul Tang; Sehrish Kanwal; James J Porter; Steffen Möller; Vang Le; Alexandru Coman; bogdang989; Valentine Svensson; Brent Pedersen; Jeff Hammerbacher; Matt Edwards; Meeta Mistry; apastore; Peter Cock; Stephen Turner.
27. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk. *The New England journal of medicine*. 2012;366(2):141-9.
28. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. *Gigascience*. 2021;10(2):giab008.
29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Research*. 2010;38(16):e164-e.
30. Thornton T, McPeck Mary S. Case-Control Association Testing with Related Individuals: A More Powerful Quasi-Likelihood Score Test. *American Journal of Human Genetics*. 2007;81(2):321-37.
31. Blum M, Chang H-Y, Chuguransky S, Grego T, Kandasaamy S, Mitchell A, et al. The InterPro protein families and domains database: 20 years on. *Nucleic Acids Research*. 2021;49(D1):D344-D54.
32. Topka S, Steinsnyder Z, Ravichandran V, Tkachuk K, Kemel Y, Bandlamudi C, et al. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2021;27(7):1997-2010.

33. Kohaar I, Zhang X, Tan S-H, Nousome D, Babcock K, Ravindranath L, et al. Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. *Nature Communications*. 2022;13(1):1361.
34. Carignan D, Lessard T, Villeneuve L, Desjardins S, Magnan S, Després P, et al. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy. *The Prostate*. 2020;80(8):632-9.
35. Feliubadaló L, Tonda R, Gausachs M, Trotta J-R, Castellanos E, López-Doriga A, et al. Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. *Scientific Reports*. 2017;7:37984-.
36. Vijai J, Topka S, Villano D, Ravichandran V, Maxwell KN, Maria A, et al. A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discov*. 2016;6(11):1267-75.
37. Kote-Jarai Z, Jugurnauth S, Mulholland S, Leongamornlert DA, Guy M, Edwards S, et al. A recurrent truncating germline mutation in the BRIP1/FANCI gene and susceptibility to prostate cancer. *British Journal of Cancer*. 2009;100(2):426-30.
38. Ray AM, Zuhlke KA, Johnson GR, Levin AM, Douglas JA, Lange EM, et al. Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. *British Journal of Cancer*. 2009;101(12):2043-7.
39. Lei H, Vorechovsky I. BACH1 517C→T transition impairs protein translocation to nucleus: A role in breast cancer susceptibility? *International Journal of Cancer*. 2003;104(3):389-91.
40. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *New England Journal of Medicine*. 2020;382(22):2091-102.
41. Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2020;26(11):2487-96.
42. Hunter SM, Rowley SM, Clouston D, Li J, Lupat R, Krishnananthan N, et al. Searching for candidate genes in familial BRCA mutation carriers with prostate cancer. *Urologic Oncology: Seminars and Original Investigations*. 2016;34(3):120.e9-.e16.
43. Johnson AM, Zuhlke KA, Plotts C, McDonnell SK, Middha S, Riska SM, et al. Mutational landscape of candidate genes in familial prostate cancer. *The Prostate*. 2014;74(14):1371-8.
44. Popanda O, Seibold P, Nikolov I, Oakes CC, Burwinkel B, Hausmann S, et al. Germline variants of base excision repair genes and breast cancer: A polymorphism in DNA polymerase gamma modifies gene expression and breast cancer risk. *International Journal of Cancer*. 2013;132(1):55-62.
45. Thorsell A-G, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L, et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. *J Med Chem*. 2017;60(4):1262-71.
46. Kwon DH-M, Borno HT, Cheng HH, Zhou AY, Small EJ. Ethnic disparities among men with prostate cancer undergoing germline testing. *Urologic Oncology: Seminars and Original Investigations*. 2020;38(3):80.e1-.e7.
47. Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. *JAMA Oncology*. 2019;5(4):523-8.
48. Shinmura K, Kato H, Kawanishi Y, Yoshimura K, Igarashi H, Goto M, et al. Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma. *Molecular Carcinogenesis*. 2017;56(2):781-8.

## FIGURE LEGENDS

### **Figure 1: Variant Filtering and Prioritisation Schematic**

Flow chart outlining genetic analysis pipeline including variant filtering and prioritisation of variants for follow up.

### **Figure 2: Age at diagnosis of DDR gene variant carriers\*\* compared to available population-based datasets.**

Age at diagnosis of variant carriers compared with a comparable population dataset (presented as proportion of individuals versus age at diagnosis). Panel A -familial prostate cancer variant carriers (n=31) overlaid with unscreened PCOR-Tas case population (n=2126); panel B- sporadic prostate cancer variant carriers (n=22) compared with unscreened PCOR-Tas population; and panel C – PROGRESS dataset variant carriers (n=28) compared with non-variant carriers from the PROGRESS dataset. \*\*DDR variant carriers = those carrying a pathogenic variant in ERCC3, BRIP1, PARP2, MUTYH, RAD51C and BRCA2.

**Table 2: DNA repair pathway genes included for analysis**

<b>Pathway</b>	<b>Number of Genes</b>	<b>Gene List</b>
Base Excision Repair	2	<i>MUTYH, PARP2</i>
Cell Cycle Regulation	5	<i>CDH1, CDKN1B, CDKN2Z, PTEN, STK11</i>
DNA Damage Response	3	<i>ATM, CHEK2, TP53</i>
Fanconi Anaemia	5	<i>BRCA2, BRIP1, PALB2, RAD51C, SLX4</i>
Homologous Recombination	9	<i>BARD1, BLM, BRCA1, GEN1, MRE11A, NBN, RAD50, RAD51D, RECQL4</i>
Mismatch Repair	7	<i>MLH1, MSH2, MSH5, MSH6, PMS2, POLD1, POLE</i>
Nucleotide Excision Repair	3	<i>ERCC2, ERCC3, XPC</i>
Included as proof-of-principle	1	<i>HOXB13</i>
<b>Total</b>	<b>36</b>	

**Table 5: Carrier frequency and statistical analysis of variants**

Gene	Variant	Australian Familial and Sporadic Prostate Cancer			North American Familial <i>PROGRESS</i> Cohort			Tasmanian Familial Prostate Cancer Study & <i>PROGRESS</i>		
		Total Carriers (% Cases)*	M <sub>QLS</sub> P-Value	M <sub>QLS</sub> Odds Ratio	Total Carriers (% Cases)*	M <sub>QLS</sub> P-Value	M <sub>QLS</sub> Odds Ratio	Total Carriers (% Cases)*	M <sub>QLS</sub> P-Value	M <sub>QLS</sub> Odds Ratio
<i>BARD1</i>	rs3738888	31 (58.1%)	0.407	1.7	4 (100%)	0.318	n.a.	35 (62.9%)	0.066	1.9
<i>BRCA2</i>	rs28897727	24 (54.2%)	0.063	n.a.	5 (80%)	0.157	n.a.	29 (58.6%)	0.193	n.a.
<i>BRIP1</i>	rs4988345	25 (64.0%)	0.118	3.1	6 (100%)	<b>0.034</b>	<b>n.a.</b>	31 (71.0%)	<b>0.025</b>	<b>3.1</b>
<i>ERCC3</i>	rs145201970	16 (50.0%)	0.554	1	5 (100%)	<b>0.010</b>	<b>n.a.</b>	21 (61.9%)	<b>2.57x10<sup>-4</sup></b>	<b>1.7</b>
<i>MUTYH</i>	rs36053993	23 (26.1%)	0.630	0.4	9 (100%)	<b>0.031</b>	<b>n.a.</b>	32 (46.9%)	0.201	0.8
<i>PARP2</i>	rs200603922	14 (71.4%)	<b>0.028</b>	<b>n.a.</b>	2 (100%)	0.388	n.a.	16 (75.0%)	0.162	n.a.

n.a. = Not Applicable, as the odds ratio cannot be calculated when no carriers in controls are identified. \*% of variant carriers that are cases.

**Table 4: Predicted pathogenicity of prioritised DDR gene variants**

Gene	Variant	Allele Change	AA Change	CADD	DANN*	SIFT	PROVEAN	PolyPhen	Mutation Taster (Rank Score)	Mutation Assessor	FATHMM† (Coding)
<i>BARD1</i>	rs3738888	G>A	R658C	26.4	0.999	0.008 (D)	-4.02 (De)	1 (P)	0.462 (D)	2.12 (M)	0.9778
<i>BRCA2</i>	rs28897727	G>T	D1420Y	15.85	0.988	0.030 (D)	-6.60 (De)	0.03 (B)	0.09 (N)	2.15 (M)	0.49798
<i>BRIP1</i>	rs4988345	G>A	R173C	25.5	0.999	0.001 (D)	-2.54 (De)	1 (P)	0.81 (D)	2.67 (M)	0.93639
<i>ERCC3</i>	rs145201970	G>A	R283C	26.7	0.999	0.000 (D)	-7.59 (De)	0.995 (P)	0.81 (D)	3.31 (M)	0.99364
<i>MUTYH</i>	rs36053993	C>T	G368D	32	0.998	0.000 (D)	-6.46 (De)	1 (P)	0.81 (D)	4.09 (H)	0.99757
<i>PARP2</i>	rs200603922	A>G	R15G	15.32	0.8	0.153 (T)	-1.04 (N)	0 (B)	0.09 (N)	0.695 (N)	0.00048

D = Damaging; T = Tolerated; De = Deleterious; N = Neutral; P = Probably Damaging; B = Benign; M = Medium; H = High. \*DANN predictions use a scoring system between 0 and 1, with scores closer to one indicating greater predicted pathogenicity. †FATHMM predictions use a scoring system between 0 and 1, with scores closer to one indicating greater predicted pathogenicity.



**Table 3: Putative pathogenic mutations identified in DDR genes in Australian discovery and North American families**


Gene	Variant	Amino Acid Change	MAF (gnomAD NFE)	CADD	Australian Discovery Familial Cohort			North American Familial Cohort		
					PrCa Affected Carriers	Total Carriers	Number of Families	PrCa Affected Carriers	Total Carriers	Number of Families
<i>ATM</i>	rs55801750	C2464R	9E-04	22.7	1	2	1	-	-	-
<i>ATM</i>	rs55982963	R2719H	1E-04	29.3	1	2	1	-	-	-
<i>ATM</i>	rs56128736	V410A	0.0021	23.1	3	6	2	2	2	1
<i>ATM</i>	rs767507047	Y2954C	6.48E-05	28.6	1	1	1	-	-	-
<i>BRCA1</i>	rs28897673	Y58C	1E-04	23.6	2	4	1	-	-	-
<i>BRCA2</i>	rs55639415	S1733F	4.71E-05	15.43	2	4	1	-	-	-
<i>BRCA2</i>	rs56403624	E462G	4.29E-04	19.02	1	1	1	-	-	-
<i>BRCA2</i>	rs786202915	F2254Y	n.a.	16.65	3	8	1	-	-	-
<i>ERCC2</i>	rs142568756	V536M	0.0005	29.1	2	4	1	-	-	-
<i>MRE11</i>	rs777373591	P132S	1.77E-05	27.2	2	4	1	-	-	-
<i>MSH6</i>	rs142254875	P943S	0.0001	22.2	2	6	1	-	-	-
<i>PMS2</i>	rs1554304601	A116V	n.a.	31	3	7	1	-	-	-
<i>POLE</i>	chr12: 133219216	P1610A	n.a.	22.8	3	9	1	-	-	-
<i>POLE</i>	rs36120395	P697R	0.0016	20.3	1	1	1	-	-	-
<i>POLE</i>	rs41561818	A1420V	0.0044	21.2	2	3	1	-	-	-
<i>PTEN</i>	rs587779989	n.a.	n.a.	19.81	3	6	1	-	-	-
<i>PTEN</i>	rs773513402	n.a.	0.0003	15.18	2	5	1	-	-	-
<i>RECQL4</i>	rs780723602	I920V	9E-06	22.3	4	11	1	-	-	-
<i>BARD1</i>	rs3738888	R188C	0.0063	26.4	2	5	1	4	4	4
<i>BRCA2</i>	rs28897727	D1420Y	0.0098	15.85	3	9	1	4	5	3
<i>BRIP1</i>	rs4988345	R173C	0.0043	25.5	2	5	1	6	6	6
<i>ERCC3</i>	rs145201970	R283C	0.0017	26.7	2	7	1	5	5	3
<i>MUTYH</i>	rs36053993	G368D	0.0047	32	2	5	2	9	9	4
<i>PARP2</i>	rs200603922	R15G	0.0012	15.32	4	6	1	2	2	2

n.a. = Not Applicable

**Table 1: Clinical characteristics of study resources with available genetic data**

	Australian Familial Cases, n (%)	Australian Sporadic Cases, n (%)	<i>PROGRESS</i> Familial Cases, n (%)
Age at Diagnosis			
<60	93 (24.54%)	137 (29.85%)	108 (33.64%)
60-64	98 (25.86%)	170 (37.04%)	75 (23.36%)
65-69	97 (20.32%)	125 (27.23%)	77 (23.99%)
≥70	107 (28.23%)	26 (5.66%)	61 (19.00%)
Missing	4 (1.06%)	1 (0.22%)	n.a.
Age at Diagnosis, Median (IQR)	64.82 (60.06-71.50)	62.59 (59.26-66.05)	63 (57.0-68.0)
Years between Diagnosis and Death			
<5	19 (5.01%)	25 (5.45%)	11 (3.43%)
5-9	39 (10.29%)	54 (11.76%)	36 (11.21%)
10-19	81 (21.37%)	103 (22.44%)	65 (20.25%)
≥20	18 (4.75%)	19 (4.14%)	7 (2.18%)
Missing	2 (0.53%)	n.a.	n.a.
n.a.	220 (58.05%)	258 (56.21%)	202 (62.93%)
Years between Diagnosis and Death, Median (IQR)	11.62 (8.75-16.10)	11.82 (7.64-15.52)	11.00 (6.50-15.0)
Cause of Death			
PrCa	49 (12.93%)	68 (14.81%)	41 (12.77%)
Other	91 (24.01%)	133 (28.98%)	72 (22.43%)
Not Processed	2 (0.53%)	n.a.	n.a.
Missing	17 (4.49%)	1 (0.22%)	6 (1.87%)
n.a.	220 (58.05%)	257 (55.99%)	202 (62.93%)
<b>Total</b>	<b>379</b>	<b>459</b>	<b>321</b>

IQR = Interquartile Range; n.a. = Not Applicable; PrCa = Prostate Cancer



**Figure 2: Age at diagnosis of DDR gene variant carriers\*\* compared to available population-based datasets**




Figure 1: Variant Filtering and Prioritisation Schematic

**Table 6: DDR variant rates by age at diagnosis**

	PrCa cases meeting criteria N (%)	Variant carriers meeting criteria* N (%)
<b>Total PrCa Cases</b>	1159	81
<b>Age at Diagnosis &lt;50 years</b>		
All PrCa cases	29 2.50%	2 6.90%
DDR variant carriers	2 2.47%	
<b>Age at Diagnosis &lt;55 years</b>		
All PrCa cases	117 10.09%	11 9.40%
DDR variant carriers	11 13.58%	
<b>Age at Diagnosis &lt;60 years</b>		
All PrCa cases	344 29.68%	20 5.81%
DDR variant carriers	20 24.69%	
<b>Age at Diagnosis &lt;65 years</b>		
All PrCa cases	693 59.79%	38 5.48%
DDR variant carriers	38 46.91%	
<b>Age at Diagnosis &lt;70 years</b>		
All PrCa cases	975 68.59%	62 6.36%
DDR variant carriers	62 76.54%	

\*Values represent the number and percentage of Tasmanian and North American cases diagnosed within the specified age bracket who carry a rare DDR risk variant.